Review of FDA Approved JAK Inhibitors for Alopecia Areata

Author(s):

Arash Mostaghimi, MD, MPH,Amy McMichael, MD

Key Takeaways

Baricitinib showed significant efficacy in maintaining hair regrowth, with 90% achieving SALT ≤20 and over 70% achieving SALT ≤10 from week 52 to 104.
Clinician- and patient-reported outcomes for eyebrow and eyelash regrowth improved between weeks 52 and 104.
TEAEs were reported in 76% of patients, mostly mild to moderate, with common events including COVID-19 infection, upper respiratory tract infection, and headache.
A single major adverse cardiovascular event was reported, with an incidence rate of less than 0.1%.

EP: 1.Impact of Alopecia Areata on Quality of Life, and Current Standard of Treatment

EP: 2.JAK Inhibitor Baricitinib for Treatment of Alopecia Areata

EP: 3.Analyzing Phase 3 Clinical Trial Data of Baricitinib in Alopecia Areata

EP: 4.Novel Mechanisms of Action for Treatment of Alopecia Areata

EP: 5.Physician and Patient Communication for the Management of Alopecia Areata

EP: 6.The Pathophysiology of Alopecia Areata

EP: 7.The Benefits of Early Diagnosis of Alopecia Areata

EP: 8.Patient Factors and Other Considerations for Treatment Selection

EP: 9.Treatment Options for Alopecia Areata

Now Viewing

EP: 10.Review of FDA Approved JAK Inhibitors for Alopecia Areata

EP: 11.JAK Inhibition in the Treatment of Alopecia Areata

EP: 12.Assessing Risk and Safety of JAK Inhibitors

EP: 13.Real-World Clinical Experience With JAK Inhibitors

EP: 14.Challenges With the Use of JAK Inhibitors

EP: 15.Considerations Regarding Patient Selection for JAK Inhibitors

EP: 16.The Role of Health Care Providers in Raising Awareness About Alopecia Areata

EP: 17.Future Directions in the Treatment of Alopecia Areata

Video content above is prompted by the following:

a. Baricitinib (n=194, long term study, Senna 2024):

i. Close to 90% of patients maintained SALT ≤20 from week 52 to week 104; SALT ≤10 was achieved by over 70% of patients; clinician- and patient-reported outcomes measurements for eyebrow and eyelash showed increase in response rates between weeks 52 and 104.

ii.TEAEs were reported in 76% of patients taking baricitinib. Most TEAEs were mild to moderate. Most common TEAEs (occurred in ≥5% patients) were COVID-19 infection, upper respiratory tract infection, and headache. One event of major adverse cardiovascular event was reported (<0.1% incidence rate).